Lin Bin X Wang

US Patent:

7179568, Feb 20, 2007

Filed:

Jul 10, 2003

Appl. No.:

10/616863

Inventors:

Francesco Cerrina - Madison WI, US
Adam Pawloski - San Jose CA, US
Lin Wang - Baton Rouge LA, US

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

G03F 9/00

US Classification:

430 5, 430 30, 430296, 430942, 430966, 430967, 382144

Abstract:

A dark-field imaging method for detecting defects in reflective lithography masks (e. g. , extreme ultraviolet (EUV) masks) used, e. g. , in processes for the fabrication of microelectronic devices. A mask blank is coated with a photoresist layer having a fluorescent dye incorporated therein. The photoresist layer is exposed to a source of radiation (e. g. , EUV radiation or glancing soft X-rays). In areas of the mask blank having defects the combined direct and reflected radiation will be insufficient fully to expose the photoresist layer. After development, photoresist will remain on the mask blank surface in areas corresponding to defects. Illumination with the excitation wavelength of the fluorescent dye reveals the location of any remaining photoresist, which can be detected using an optical microscope, thereby to detect defects in the mask blank.

US Patent:

7553653, Jun 30, 2009

Filed:

Sep 19, 2005

Appl. No.:

11/230374

Inventors:

Emilio Kakkis - Novato CA, US
Daniel Oppenheimer - Castro Valley CA, US
Paul Fitzpatrick - Albany CA, US
Robert Heft - D.D.O., CA
Alejandra Gamez - San Diego CA, US
Lin Wang - San Diego CA, US
Woomi Kim - Busan, KR
Mary Straub - Malibu CA, US
Marianne Patch - San Diego CA, US
Raymond C. Stevens - La Jolla CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA
The Scripps Research Institute - La Jolla CA

International Classification:

C12N 9/88

US Classification:

435232

Abstract:

The present invention pertains to the use of the protein phenylalanine ammonia-lyase, as well as the biologically-active derivatives of the said protein for preventing or treating diseases associated with a phenylalanine imbalance in a human or animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating a phenylalanine imbalance in vivo. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting more therapeutically-effective variants of said protein as well as to the selected variants themselves.

US Patent:

20180216095, Aug 2, 2018

Filed:

Mar 29, 2018

Appl. No.:

15/940803

Inventors:

- San Diego CA, US
Lin Wang - San Diego CA, US
H. Michael Shepard - San Diego CA, US

International Classification:

C12N 9/78
A61K 38/48
A61K 38/00

Abstract:

Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.

US Patent:

20170166878, Jun 15, 2017

Filed:

Apr 8, 2016

Appl. No.:

15/094908

Inventors:

- San Diego CA, US
Lin Wang - San Diego CA, US
H. Michael Shepard - San Diego CA, US

International Classification:

C12N 9/78
A61K 38/48

Abstract:

Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.